Targeting a KRAS neoantigen peptide vaccine to DNGR-1 dendritic cells
Published: 27 Nov 2020
Views: 230
Dr Rachel Ambler - The Francis Crick Institute, London, United Kingdom
Dr Rachel Ambler speaks to ecancer about her presentation at the ENA virtual meeting this year.
She discussed mutations in the KRAS gene, notable in pancreatic, lung, and colorectal cancers.
Dr Ambler's research aims to find new treatments and combinations to treat these cancers with KRAS mutations. Recently, using an immune response has seemed promising, which is Dr Ambler's current research.
She explores some of the options in this realm of treatment, specifically the use of DNGR-1 expressing cells to stimulate a T-cell response - studies are promising and ongoing.
- Categories:
- Colorectal & gastro
- Hepatobiliary pancreatic
- Lung & pleura
- Complementary medicine
- Personalised medicine
- Medicines
- Technology & innovation
- Biology
- Causes of cancer
- Control, survivorships & outcomes
- Detection, diagnosis & prognosis
- Antibodies & immunotherapy
- Cell therapy & stem cells
- Cytotoxics
- Drug development
- Targeted molecules
- Vaccines & virus
Related Videos
Five year update of ECHELON-1 for classical Hodgkin lymphoma
Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil
8 Dec 2020
ESMO 2020 melanoma roundup
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
28 Sep 2020
PARP inhibitors and their evolving role for the treatment of prostate cancer
Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi
24 Sep 2020
OncoAlert and ecancer weekly roundup for September 6-13, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
14 Sep 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
30 Jun 2020
The potential of KRAS inhibitors for non-small-cell lung cancer
Prof Reinhard Büttner - University Hospital Cologne, Cologne, Germany
22 Apr 2020
An overview of the latest advances in gastric cancer
Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium
17 Jul 2019
Comment: POLO III trial for metastatic pancreatic cancer
Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA
24 Jun 2019
Chemoimmunotherapy or BTK inhibition for patients with CLL
Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany
20 Jun 2019
